Replies to post #78565 on Anavex Life Sciences Corp (AVXL)

[McMagyar]

Not qualified to answer. Risk of
Younger patient is the point..
I don't know enough about Rett Syndrome either.
With elderly PArkinsons and ADS population
The risk return on almost any treatment may be justified, but if you are dealing with a population whose life is not being immediately threatened, than you need to be more cautious from a patient and company perspective.
We all feel very confident that A2-73 poses limited if not zero risk as a small molecule, sigma 1 agonist.. and Pharmkokinetics may also add to this belief, but the best way at this point to actually demonstrate safety is through in human trials. I am willing to sign up right now! Bet you could find a few million more at the drop of a pin..Anavexnow!